FDA’s Division of Drug Information in the Center for Drug Evaluation and Research (CDER) is excited to present a series of educational webinars targeting the needs of all health care professionals and students, including physicians, physician assistants, nurses, pharmacists, and pharmacy technicians. Interact with FDA staff from a variety of divisions and learn more about the FDA and drug regulation!
On Tuesday, June 22, 2021, CDER's Office of Communication, Division of Drug Information (DDI) hosted a webinar titled: FDA Drug Topics: Overview of Risk Evaluation and Mitigation Strategies (REMS) for Health Care Providers. This webinar provided an overview of REMS and discussed how the REMS safety requirements impact prescribers, dispensers and patients. Participants should gain an understanding of the REMS authorities, how REMS are implemented, and the entities that provide oversite and support. REMS is a drug safety program that the FDA can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. REMS are designed to reinforce medication use behaviors and actions that support the safe use of that medication. While all medications have labeling that informs health care stakeholders about medication risks, only a few medications require a REMS.
View Presentation Here: https://collaboration.fda.gov/p5xnu3p87dgi/
Download Presentation Slides: Overview of Risk Evaluation and Mitigation Strategies (REMS) for Health Care Providers (PDF - 1.68MB)
Activity Outline and Continuing Education Information: Overview of Risk Evaluation and Mitigation Strategies (REMS) for Health Care Providers (PDF - 168KB)
If you have never attended an Adobe Connect meeting before (Google Chrome (preferred) or Firefox 43 or higher):
Test your connection: Adobe Connect Diagnostic Test
Get a quick overview: Discover Adobe Connect Solutions
Adobe, the Adobe logo, Acrobat and Adobe Connect are either registered trademarks or trademarks of Adobe Systems Incorporated in the United States and/or other countries.